The incidence of candidiasis among immunocompromised patients and emergence of antimycotics resistant strains has increased significantly. The aims of this study were: to examine the in vitro activity of antimycotics and biocides against Candida clinical isolates; to detect cross-resistance of fungi to these preparations and to estimate whether disinfectants applied in hospital areas are active against clinical Candida isolates. In vitro susceptibility of 102 Candida isolates to eight antimycotics was examined by Etest and ATB Fungus. Sensitivity of these strains to four disinfectants and an antiseptic agent was tested according to EN 1275:2005. Amphotericin B, caspofungin and 5-fluorocytosine were the most effective antimycotics against all Candida isolates. Resistance to itraconazole and fluconazole was observed among C. krusei and C. glabrata. The MICs (Minimal Inhibitory Concentrations) for ketoconazole, voriconazole and posaconazole against Candida albicans ranged: 0.003 ->32 µg/ml and one strain was resistant to three agents tested. All analysed Candida strains were sensitive to biocides containing either chlorine, aldehyde, alcohol mixtures, glucoprotamin or chlorhexidine gluconate with isopropanol. Sensitivity to these agents was observed at concentrations lower than those concentrations recommended by manufacturers to achieve proper biocidal activity to those preparations. Our data suggest that these disinfectants can be effectively applied in clinical wards to prevent nosocomial Candida infections.
Introduction
In the past few years the incidence of candidiasis, particularly among immunocompromised patients, has increased significantly. Although Candida albicans is still the most common strain resulting in yeast infections, contributing towards both invasive and non-invasive forms of candidiasis, the number of patients infected by C. glabrata, C. tropicalis, C. parapsilosis and C. krusei has increased in recent years [1] [2] [3] . Microorganisms prevalent in the hospital environment can potentially colonise patients and cause infections. Moreover, fungi can persist for extended periods of time on different surfaces, which hospitalised patients and the caregivers are in routine contact with. Consequently this can lead to the spread of nosocomial yeast infections [4] .
Controlling the population of such microorganisms in the hospital environment is the most effective way to diminish the prevalence of these infections.
Studies testing the susceptibility of Candida spp. strains isolated from different clinical materials to antifungal agents have been published widely [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, data concerning the susceptibility of clinical yeast isolates both to antifungal drugs and fungicidal agents used for disinfection and antisepsis procedures are limited. In particular, the efficacy of chemical disinfection procedures toward clinical fungal isolates have rarely been evaluated [14] . Unfortunately, inadequate disinfection programmes implemented in hospitals are still regarded as one of the major factors causing outbreaks of nosocomial infections [15] . To reduce the spread of infection, it is necessary that appropriate disinfecting agents are used on hospital medical devices, equipment, furniture and other items, should by applied on skin of personnel and patients.
The aim of this investigation was to evaluate the in vitro susceptibility of clinical isolates of different Candida spp. to antimycotics, disinfectants and an antiseptic agent used to treat patients, disinfect surfaces, medical devices and also used as hygienic hand rubs. (9) , drain swabs (20) and other samples (11) .
Experimental Procedures

Yeast isolates
Strains were isolated during routine clinical microbiological investigations and identified by biochemical tests -API 20C AUX (bioMérieux, Lyon, France) and chromogenic medium: CHROMagar Candida (bioMérieux, Lyon, France). Strain preservation and subculturing prior to testing was conducted as described previously by Staniszewska et al. [16] .
Antimycotics susceptibility testing
To examine yeast susceptibility, Etests were applied for 4 antifungal drugs: ketoconazole, voriconazole, posaconazole and caspofungin. Information (EAS 006) concerning performance of the assay and interpretation of the inhibition area in relation to the Minimal Inhibitory Concentration (MIC) value was provided by the Etest producer [9] .
The MICs≥4 µg/ml of voriconazole and posaconazole as well as MIC >2 µg/ml of caspofungin indicated resistance of the isolates. Strains treated with ketoconazole showing MIC >32 µg/ml were considered resistant.
Each set of clinical isolates was evaluated in reference to two quality control strains, recommended by the CLSI M27-A3 guideline: C. krusei ATCC 6258 and C. parapsilosis ATCC 22019. Additionally, the standard C. albicans ATCC 90028 strain recommended by the Etest manufacturer was used to verify the obtained results.
The susceptibility of strains to amphotericin B, 5-fluorocytosine, itraconazole, and fluconazole, was routinely tested by automatic BioMérieux system -ATB Fungus. Resistance (R) was interpreted using manufacturer recommendations: 5-fluorocytosine (MIC≥32 µg/ml), itraconazole (MIC≥1 µg/ml) and fluconazole (MIC≥64 µg/ml). In compliance with the manufacturer guidelines, isolates showing MIC>2 μg/ml for amphotericin B were classified as resistant.
In the case of resistant isolates testing was repeated separately.
Disinfectant agents susceptibility testing
Disinfectants examined in this study were classified based on their different active agents, including: chlorine-releasing agent (Medicarine), aldehyde mixture (Lysoformine 3000), alcohol mixture (Incidin Liquid Spray), glucoprotamin (Incidin Plus). Additionally an antiseptic agent containing chlorhexidine gluconate and isopropanol (Spitaderm) was also tested.
The basic fungicidal activity was assessed by suspension test method, according to the European Standardization Committee (CEN) European standard EN 1275:2005 [17] , as previously described by Staniszewska et al. [16] . Clinical Candida isolates and standard strain (C. albicans ATCC 10231) cell suspensions were adjusted to 1.5-5.0 x 10 7 cfu/ml. Different, two-fold serial dilutions of the disinfectants and an antiseptic agent were prepared. Studied preparations were tested in different concentration ranges: Medicarine: 40-160 mg/l, Lysoformine 3000: 0.02-0.32%, Incidin Liquid Spray: 10-80%, Incidin Plus: 0.06-0.48% and Spitaderm: 10-80%. The number of cells per ml in the test mixture at the beginning of the study and the number of surviving yeast cells after 5 min of contact time was counted and expressed as logarithmic reduction factor [17] . The lowest product concentration exhibiting biocidal activity (at least 4 log reduction of fungal cells counts) was determined.
Results
In vitro antifungal drugs susceptibility profile of Candida strains
Amphotericin B and caspofungin were highly active against all isolates. It was also found that 5-fluorocytosine was active -indicated by only 2 of 10 C. tropicalis isolates among all analysed Candida spp.
strains exhibiting resistance. The susceptibility pattern of the 102 analysed Candida spp. strains to different 5 azole antifungal chemotherapeutics was determined. Etest data are presented in Table 1 .
Only one isolate (C. albicans) was resistant to all five azoles tested while three other C. albicans strains were resistant to three azoles tested and 16 isolates were resistant to two azoles tested. Four strains (3/49 C. albicans and 1/23 C. glabrata) were resistant both to posaconazole and voriconazole. Three of these strains also exhibited resistance to ketoconazole and one strain was resistant to itraconazole and fluconazole. Six strains (3/49 C. albicans and 3/29 C. glabrata) were resistant to posaconazole, but susceptible to voriconazole. Two of these strains were also resistant to ketoconazole and two to itraconazole. Eight C. albicans isolates were resistant to voriconazole; yet, susceptible to posaconazole; four of them were also resistant to ketoconazole.
All C. krusei isolates were resistant to fluconazole, but no one of C. tropicalis and C. parapsilosis were resistant to this agent.
Sensitivity of Candida clinical strains to biocides
Comparison of the yeasticidal activity (at least 4 log reduction /≥99.99%/ of the tested yeast cell count after 5 min of contact time at 20°C) of chosen chemical disinfectants and antiseptic showed high susceptibility of the analysed clinical yeasts strains. Table 2 presents the characteristics of each agent and their concentration necessary to achieve reduction of yeast cell counts according to EN standards under applied conditions.
The biocidal activity of tested agents, according to the EN-1275 standard, was observed for concentrations lower than recommended by manufacturers. For some agents the required by EN-1275 microbial count reduction was observed for very low concentration of preparations (e.g. 1/50 Lysoformine 3000 and 1/33 Incidin Plus), even for 3-fold shorter contact time than recommended by manufacturers. No differences in the susceptibility of strains among different Candida species were observed. The susceptibility to disinfectants of tested strains characterized by decreased susceptibility to antifungal drugs was comparable to that observed for other tested strains.
Discussion
The Clinical and Laboratory Standard Institute recommends the microbroth dilution assay as the reference method for antifungal susceptibility testing of yeasts [18] . However, in many clinical laboratories agar diffusion method with application of Etest (AB Biodisk, Solna, Sweden) is also used as a quick and reliable method of testing susceptibility [19] [20] . Comparison of the in vitro susceptibility to antimycotics of strains examined in this study by Etest and ATB Fungus system, with data presented by other authors, led to following conclusions:
Amphotericin B is a very potent agent, which is in agreement with the infrequent observed resistance of Candida spp. to this chemotherapeutic reported elsewhere [5, 6, 10, 11] . Falagas et al. [13] observed high effectiveness of caspofungin -a new echinocandin exhibiting lower toxicity in comparison to amphotericin B, in the treatment of patients with fungal infections caused mainly by Candida spp. In our study, caspofungin was also found to be very effective as indicated by the complete absence of resistance observed in the tested strains.
5-fluorocytosine ellicited moderate activity against C. glabrata, C. krusei and C. tropicalis, while all tested strains of C. albicans and C. parapsilosis were susceptible to this agent. Similar results were obtained by Quindos et al. [12] .
Susceptibility of Candida to triazoles of the first generation, namely, itraconazole and fluconazole, depended on the examined species and varied in different studies. In a large prospective surveillance study Safdar et al. [7] noticed that 15.2% and 10.7% of C. glabrata isolates were resistant to itraconazole and fluconazole, respectively. In our study only 5/49 of C. albicans isolates turned out to be resistant to itraconazole, but approximately half of the C. glabrata isolates, were resistant to itraconazole and fluconazole. All C. krusei strains tested in our studies as well as in studies of other groups [6, 12] were resistant to fluconazole, suggesting intrinsic resistance of these strains.
Voriconazole, a second generation triazole compound, has previously been analyzed by a number of studies. Swinne et al. [6] reported that all C. parapsilosis isolates were susceptible to voriconazole, but C. tropicalis and C. glabrata isolates showed a wide diversity in susceptibility. Pfaller et al. [9] reported high susceptibility of C. krusei to voriconazole. In accordance with data obtained in our study, Wakieć et al. [21] also described the existence of C. albicans isolates with decreased susceptibility to voriconazole.
Analysis of the combined in vitro susceptibility patterns of different Candida spp. isolates to azole compounds obtained in 8 European multi-institutional surveys [9] leads to conclusion that both old and new azoles are active against the majority of tested isolates.
The occurrence of different microorganisms, often resistant to high concentrations of antibiotics and chemotherapeutics, especially among hospitalized patients, their presence on the surfaces of medical devices, hard surfaces, linen and in health care facilities, necessitates improved antisepsis and disinfection procedures using effective antimicrobial preparations [16, 22] . The CEN has established several EN standards in order to standardize the methods applied for testing antifungal activity of antiseptic and disinfectant agents. [16, 22, 23] .
Yeasts strains of clinical origin used in this study were found to be susceptible to disinfectants and antiseptic containing different active substances. There were no significant differences in the susceptibility of strains to fungicidal agents, regardless of the antimycotic susceptibility patterns of isolates. Taken altogether, the results from this study show that the tested disinfectants remain effective against clinical Candida spp. isolates. Therefore it can be expected that if they are transmitted from patients to hospital environment, proper disinfection with agents tested, will be effective.
